BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc. (BBOT) Revenue
Annual & quarterly revenue history · segment & region breakdown
BBOT · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsBridgeBio Oncology Therapeutics Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2021 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | — |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare BBOT revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income BridgeBio Oncology Therapeutics Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
BridgeBio Oncology Therapeutics Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from BridgeBio Oncology Therapeutics Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
BBOT revenue · 4 questionsBBOT's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · BridgeBio Oncology Therapeutics Inc. SEC filings · GAAP · BridgeBio Oncology Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026